Delta Air Lines, Inc. (DAL) Stock Price Today
Aura AI Summary
Key Stats
- $57.37BMarket Cap
- 6,120,637Volume
- IndustrialsSector
- $93.6652W High
- $55.7652W Low
- 99 DaysTypical Hold Time
- $72.42BEnterprise Value
- 0.99%Div Yield
- 89% Sell | 11% BuyTrading Activity
Track Delta Air Lines, Inc. (DAL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Delta Air Lines, Inc. has traded between a low of $55.76 and a high of $93.66, highlighting its annual price range. Buy and sell Delta Air Lines, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Most Recent News
Trogenix appoints John Young as Chair and Josh Murray as Non-Executive Director to boost global growth and US expansion.
Trogenix, a clinical-stage precision oncology company, has appointed John Young as Chair and Josh Murray as Non-Executive Director to support its global strategy, commercial growth, and US expansion. John Young brings over 35 years of pharmaceutical ...

Wellington Management Group crosses 5% voting rights threshold in Admiral Group PLC shares.
Wellington Management Group LLP has notified that it crossed the 5% voting rights threshold in Admiral Group PLC as of November 6, 2026. The group holds a total of 5.01% voting rights through direct shares and financial instruments. This disclosure i...

Roche unveils new Alzheimer’s drug and diagnostic data at CTAD 2026, advancing treatment and early detection.
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.